MRNA
Moderna, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 10,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "15ed79d9-9ee1-44f2-aaa2-d6d085777356",
"title": "Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?",
"description": "Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.",
"keywords": "",
"snippet": "Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi...",
"url": "https://finance.yahoo.com/news/does-soaring-novavax-stock-enough-091100027.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/238ZwlMCJKJhXWhqc718sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTk-/https://media.zenfs.com/en/motleyfool.com/47f737596006571fd18c910df96d4a0b",
"language": "en",
"published_at": "2024-05-14T09:11:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.071117,
"sentiment_score": -0.369933,
"highlights": [
{
"highlight": "., isn't like the mRNA vaccines from <em>Moderna</em> and Pfizer. Instead of goading your body's cellular machinery to make a protein that resembles the surface of the SARS-CoV-2 virus, Nuvaxovid is an injection of a similar protein already manufactured by moth cells.\n\nA more traditional approach to vaccine manufacturing suits Sanofi.",
"sentiment": -0.1128,
"highlighted_in": "main_text"
},
{
"highlight": "Risks ahead of Novavax\n\nComirnaty from Pfizer and Spikevax from <em>Moderna</em> have both earned full approval from the U.S. Food and Drug Administration (FDA). Nuvaxovid is fully approved for marketing throughout the European Union but it's only available under an Emergency Use Authorization in America.",
"sentiment": -0.2187,
"highlighted_in": "main_text"
},
{
"highlight": "The Motley Fool recommends <em>Moderna</em>. The Motley Fool has a disclosure policy.\n\nDoes Soaring Novavax Stock Have Enough Fuel to Climb Higher? was originally published by The Motley Fool",
"sentiment": -0.7783,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "a5dcc260-9ce2-48ef-87cd-29b082fe8f9d",
"title": "Nasdaq legt zu, Apple-Aktie auf dem Vormarsch",
"description": "Die US-Börsen starteten uneinheitlich in die neue Woche. Die Technologie-Börse konnte zulegen. Apple, Intel und Moderna notierten im Plus.",
"keywords": "",
"snippet": "E-Mail\n\nTeilen\n\nMehr\n\nTwitter\n\nDrucken\n\nFeedback\n\nFehler melden Sie haben einen Fehler gefunden? Bitte markieren Sie die entsprechenden Wörter im Text. Mit nur...",
"url": "https://www.focus.de/finanzen/boerse/abendboerse-nasdaq-legt-zu-apple-aktie-auf-dem-vormarsch_id_259941724.html",
"image_url": "https://p6.focus.de/img/fotos/id_259739822/wall-street.jpg?im=Crop%3D%280%2C260%2C3463%2C1732%29%3BResize%3D%281200%2C627%29&impolicy=perceptual&quality=mediumHigh&hash=d52d606a0a19fca959b81399a3d0b4e16e3748a08719cab5e3a6895d64afc7b9",
"language": "de",
"published_at": "2024-05-14T05:36:12.000000Z",
"source": "rss.focus.de",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 34.928665,
"sentiment_score": null,
"highlights": [
{
"highlight": "Apple, Intel und <em>Moderna</em> notierten im Plus.\n\nDer US-Leitindex Dow Jones Industrial schloss am Montag bei 39.431 Punkten. Damit verbuchte er ein Minus von 0,21 Prozent. Der technologielastige Nasdaq hingegen gewann 0,21 Prozent auf 18.198 Zähler. Stärkste Werte im Dow waren Intel, Nike und Apple mit Gewinnen um die zwei Prozent.",
"sentiment": -0.8625,
"highlighted_in": "main_text"
},
{
"highlight": "Im Nasdaq gewann <em>Moderna</em> als Tagessieger gut sieben Prozent. Meta tendierte schwächer und verlor 1,7 Prozent. Zahlreiche Unternehmen präsentieren Quartalszahlen, auch Rheinmetall Am Dienstag erwarten Anleger in Deutschland Quartalszahlen von Bayer, Brenntag, EnBW, Fraport, Hannover Rück und Porsche Automobil Holding SE.",
"sentiment": -0.8625,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "fa7d532f-9472-488e-a875-81ce90eda39c",
"title": "S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan",
"description": "The S&P 500 finished flat on Monday, May 13, 2024, amid concerns about rising prices ahead of inflation data due later in the week.",
"keywords": "",
"snippet": "Key Takeaways The S&P 500 finished flat on Monday, May 13, 2024, amid concerns about rising prices ahead of inflation data due later in the week.\n\nIncyte shares...",
"url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-incyte-stock-pops-on-buyback-plan-8647812",
"image_url": "https://www.investopedia.com/thmb/GKql0ln5qboXaatNt4Z5FFsewQc=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1493093301-4af383e124cf49858117a9b3c98556f5.jpg",
"language": "en",
"published_at": "2024-05-13T21:23:12.000000Z",
"source": "investopedia.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.17813,
"sentiment_score": 0.51465,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA) shares gained 7.1%, clawing back the losses posted Friday after the biotech firm said the Food and Drug Administration (FDA) had delayed its approval decision on mRNA-1345, the company's vaccine against respiratory syncytial virus (RSV).",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "The delay puts <em>Moderna</em> at a disadvantage versus GSK (GSK) and Pfizer (PFE), whose RSV vaccines have already received approval, but <em>Moderna</em> still expects a commercial launch in the third quarter of 2024. In addition, Morningstar included <em>Moderna</em> on a list of undervalued stocks on Monday, projecting the firm will be profitable by 2026.",
"sentiment": 0.5187,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d86733fe-4154-491d-9ce7-65c7ef03f2c8",
"title": "Рынок акций США закрылся разнонаправленно, Dow Jones снизился на 0,21% От Investing.com",
"description": "Рынок акций США закрылся разнонаправленно, Dow Jones снизился на 0,21%",
"keywords": "",
"snippet": "Investing.com – Фондовый рынок США завершил торги понедельника разнонаправленно за счет укр?...",
"url": "https://ru.investing.com/news/stock-market-news/article-2419110",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPED0307W_L.jpg",
"language": "ru",
"published_at": "2024-05-13T20:30:48.000000Z",
"source": "ru.investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.05478,
"sentiment_score": null,
"highlights": [
{
"highlight": "В лидерах роста среди компонентов индекса S&P 500 по итогам сегодняшних торгов были акции Incyte Corporation (NASDAQ: ), которые подорожали на 8,56% до отметки 57,60, <em>Moderna</em> <em>Inc</em> (NASDAQ: ), которые набрали 7,13%, закрывшись на уровне 125,67, а также акции Walgreens Boots Alliance Inc (NASDAQ: ), которые повысились на 5,41%, завершив сессию на отметке",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b4d8f3a8-f9b6-4728-95f4-d36a2895edc1",
"title": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.21% By Investing.com",
"description": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.21%",
"keywords": "",
"snippet": "Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the , and sectors led shares higher while losses in the , and sectors led shares...",
"url": "https://www.investing.com/news/stock-market-news/us-stocks-mixed-at-close-of-trade-dow-jones-industrial-average-down-021-3438021",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPECBL0J0_L.jpg",
"language": "en",
"published_at": "2024-05-13T20:30:24.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.889008,
"sentiment_score": 0.5267,
"highlights": [
{
"highlight": "The top performers on the S&P 500 were Incyte Corporation (NASDAQ: ) which rose 8.56% to 57.60, <em>Moderna</em> <em>Inc</em> (NASDAQ: ) which was up 7.13% to settle at 125.67 and Walgreens Boots Alliance Inc (NASDAQ: ) which gained 5.41% to close at 18.12.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "0c45de1c-0929-4eb6-b8fe-1ac8a16025a0",
"title": "Unveiling Moderna (MRNA)'s Value: Is It Really Priced Right? A Comprehensive Guide",
"description": "Moderna Inc (MRNA) has recently shown a notable daily gain of 5.55%, with a three-month gain of 34.21%. Despite these impressive numbers, a deeper look into the",
"keywords": "GuruFocus, Article, News, GuruFocus Research, MRNA",
"snippet": "Moderna Inc (MRNA, Financial) has recently shown a notable daily gain of 5.55%, with a three-month gain of 34.21%. Despite these impressive numbers, a deeper lo...",
"url": "https://www.gurufocus.com/news/2436118/unveiling-moderna-mrnas-value-is-it-really-priced-right-a-comprehensive-guide",
"image_url": "https://static.gurufocus.com/logos/0C0000BJB3.png?13",
"language": "en",
"published_at": "2024-05-13T15:31:53.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 37.724377,
"sentiment_score": 0.69608,
"highlights": [
{
"highlight": "<em>Moderna</em> <em>Inc</em> (MRNA, Financial) has recently shown a notable daily gain of 5.55%, with a three-month gain of 34.21%. Despite these impressive numbers, a deeper look into the company's financials reveals a Loss Per Share of 15.67.",
"sentiment": 0.7207,
"highlighted_in": "main_text"
},
{
"highlight": "Company Overview\n\nFounded in 2010 and going public in December 2018, <em>Moderna</em> is a commercial-stage biotech leader that gained rapid validation with its COVID-19 vaccine authorized in the United States in December 2020.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "With 39 mRNA development candidates in clinical trials covering areas like infectious disease, oncology, and cardiovascular disease, <em>Moderna</em> is at the forefront of biotechnological innovation.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\nWhile <em>Moderna</em> <em>Inc</em> (MRNA, Financial) exhibits strong financial health and impressive growth, its current valuation far exceeds its intrinsic value as estimated by GF Value, indicating significant overvaluation. Potential investors should be cautious, considering the possible lower long-term returns.",
"sentiment": 0.9042,
"highlighted_in": "main_text"
},
{
"highlight": "Unveiling <em>Moderna</em> (MRNA)'s Value: Is It Really Priced Right? A Comprehensive Guide",
"sentiment": 0.5709,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7f998610-2276-4690-a95a-bfb58362f8fd",
"title": "Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine",
"description": "Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2272961/moderna-mrna-falls-as-fda-extends-review-time-for-rsv-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272961",
"image_url": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
"language": "en",
"published_at": "2024-05-13T15:25:00.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.881794,
"sentiment_score": 0.128,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA) Falls as FDA Extends Review Time for RSV Vaccine",
"sentiment": 0.128,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7649b1dc-e027-4301-b79b-d319752b4d60",
"title": "Moderna apre in positivo: +4,90% a New York",
"description": "La società biotecnologica americana Moderna ha mostrato un forte incremento nelle sue quotazioni, segnando un guadagno significativo. Nonostante una recente debolezza rispetto al Nasdaq 100, le prospettive a medio termine rimangono positive. L’analisi tecnica suggerisce però una potenziale correzione nel breve termine.",
"keywords": "",
"snippet": "Un salto notevole nel valore di Moderna, la colosso biotecnologico degli Stati Uniti, ha catturato l’attenzione con un aumento del 4,90%. Questo balzo si cont...",
"url": "https://www.finanza.com/news/moderna-apre-in-positivo-490-a-new-york",
"image_url": "https://www.finanza.com/app/uploads/2024/05/imported-moderna.jpeg",
"language": "it",
"published_at": "2024-05-13T14:36:15.000000Z",
"source": "finanza.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.72187,
"sentiment_score": null,
"highlights": [
{
"highlight": "Un salto notevole nel valore di <em>Moderna</em>, la colosso biotecnologico degli Stati Uniti, ha catturato l’attenzione con un aumento del 4,90%. Questo balzo si contrappone ad un momento di minor forza quando comparato all’indice Nasdaq 100, sollevando la possibilità che il mercato possa considerare il momento adatto per vendere le azioni.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Guardando ai trend di medio termine, l’ottimismo per <em>Moderna</em> persiste, nonostante un recente rallentamento evidenziato dall’analisi del grafico a breve termine. Qui, si nota un calo delle quotazioni al momento del test della resistenza a 124,6 USD, con un primo livello di supporto identificato a 120,3 USD.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> apre in positivo: +4,90% a New York",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7f9efd6a-8315-4eaa-8199-fabe3431cb99",
"title": "Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know",
"description": "Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2272679/investors-heavily-search-moderna-inc-mrna-here-is-what-you-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|most_searched_stocks_-_v1-2272679",
"image_url": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
"language": "en",
"published_at": "2024-05-13T13:00:10.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 71.59933,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Investors Heavily Search <em>Moderna</em>, <em>Inc</em>. (MRNA): Here is What You Need to Know",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "3c30aafb-9d2b-4507-a7f1-0340e77f1c53",
"title": "Novo Nordisk: Συμφωνία ύψους 600 εκατ. δολαρίων με την Metaphore Biotechnologies για φάρμακα κατά της παχυσαρκίας",
"description": "Η συνεργασία με τη Metaphore Biotechnologies έχει ως στόχο την ανάπτυξη έως και δύο φαρμάκων.",
"keywords": "",
"snippet": "Η συνεργασία με τη Metaphore Biotechnologies έχει ως στόχο την ανάπτυξη έως και δύο φαρμάκων.\n\nΗ Novo Nor...",
"url": "https://www.fortunegreece.com/article/novo-nordisk-simfonia-ipsous-600-ekat-dolarion-me-tin-metaphore-biotechnologies-gia-farmaka-kata-tis-paxisarkias/",
"image_url": "https://www.fortunegreece.com/wp-content/uploads/2023/09/18923644.jpg",
"language": "el",
"published_at": "2024-05-13T12:02:15.000000Z",
"source": "fortunegreece.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.860596,
"sentiment_score": null,
"highlights": [
{
"highlight": "Όπως και τα υπόλοιπα πρότζεκτ της Novo Nordisk με τη Flagship, την εταιρεία venture capital η οποία βρίσκεται πίσω από την αμερικανική εταιρεία παραγωγής εμβολίων <em>Moderna</em> <em>Inc</em>., η συνεργασία με τη Metaphore θα επικεντρωθεί στην πρώιμη έρευνα η οποία θα διαρκέσει ακόμα αρκετά χρόνια και θα καθυστερήσει να φτάσει στα χέρια των ασθενών.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "MRNA",
"total_documents": 10,
"sentiment_avg": 0.24924950549999872
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us